Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study
<p>Abstract</p> <p>Background</p> <p>A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two po...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-02-01
|
| Series: | Annals of General Psychiatry |
| Online Access: | http://www.annals-general-psychiatry.com/content/8/1/5 |
| _version_ | 1818380225305640960 |
|---|---|
| author | Wu Jasmanda Mahmoud Ramy Pandina Gahan Gianfrancesco Frank D Wang Ruey H |
| author_facet | Wu Jasmanda Mahmoud Ramy Pandina Gahan Gianfrancesco Frank D Wang Ruey H |
| author_sort | Wu Jasmanda |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics.</p> <p>Methods</p> <p>Treatment episodes with risperidone, clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, haloperidol, perphenazine and 'other typical' antipsychotics were identified in two databases (large commercial, Medicaid). Comparisons used proportional hazards regression to determine whether prolactin testing was disproportionate with risperidone, regardless of prior potentially prolactin-related adverse events (PPAEs). Logistic regression determined whether magnetic resonance imaging (MRI)/computed tomography (CT) were disproportionate in risperidone-treated patients vs other patients, regardless of hyperprolactinemia or PPAEs. In each regression, the 'other typical' antipsychotic category served as the comparator. Regression models controlled for age, gender, and other factors.</p> <p>Results</p> <p>Altogether, 197,926 treatment episodes were analyzed (63,878 risperidone). Among patients with or without preceding PPAEs, risperidone treatment was associated with a significantly greater likelihood of prolactin assessment (hazard ratio (HR) 1.34, 95% confidence interval (CI) = 1.09 to 1.66, p = 0.007). Among patients with hyperprolactinemia or PPAEs, those treated with risperidone (odds ratio (OR) 1.66, 95% CI 1.23 to 2.23, p = 0.001) or ziprasidone (OR 1.66, 95% CI 1.06 to 2.62, p = 0.028) had a higher likelihood of MRI/CT.</p> <p>Conclusion</p> <p>Risperidone-treated patients are more likely to undergo prolactin assessment regardless of prior PPAEs, and more likely to undergo MRI/CT in association with hyperprolactinemia or PPAEs. Thus, a predisposition for more evaluations in risperidone-treated patients may contribute to disproportionate identification and reporting of prevalent pituitary adenoma.</p> |
| first_indexed | 2024-12-14T02:15:18Z |
| format | Article |
| id | doaj.art-e4be64b9dac349f69801fc676ced2193 |
| institution | Directory Open Access Journal |
| issn | 1744-859X |
| language | English |
| last_indexed | 2024-12-14T02:15:18Z |
| publishDate | 2009-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Annals of General Psychiatry |
| spelling | doaj.art-e4be64b9dac349f69801fc676ced21932022-12-21T23:20:38ZengBMCAnnals of General Psychiatry1744-859X2009-02-0181510.1186/1744-859X-8-5Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based studyWu JasmandaMahmoud RamyPandina GahanGianfrancesco Frank DWang Ruey H<p>Abstract</p> <p>Background</p> <p>A reporting association of risperidone with pituitary tumors has been observed. Because such tumors are highly prevalent, there may be other reasons why they were revealed in association with risperidone treatment. We assessed two potential explanations: disproportionately more prolactin assessment and head/brain imaging in risperidone-treated patients vs patients treated with other antipsychotics.</p> <p>Methods</p> <p>Treatment episodes with risperidone, clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, haloperidol, perphenazine and 'other typical' antipsychotics were identified in two databases (large commercial, Medicaid). Comparisons used proportional hazards regression to determine whether prolactin testing was disproportionate with risperidone, regardless of prior potentially prolactin-related adverse events (PPAEs). Logistic regression determined whether magnetic resonance imaging (MRI)/computed tomography (CT) were disproportionate in risperidone-treated patients vs other patients, regardless of hyperprolactinemia or PPAEs. In each regression, the 'other typical' antipsychotic category served as the comparator. Regression models controlled for age, gender, and other factors.</p> <p>Results</p> <p>Altogether, 197,926 treatment episodes were analyzed (63,878 risperidone). Among patients with or without preceding PPAEs, risperidone treatment was associated with a significantly greater likelihood of prolactin assessment (hazard ratio (HR) 1.34, 95% confidence interval (CI) = 1.09 to 1.66, p = 0.007). Among patients with hyperprolactinemia or PPAEs, those treated with risperidone (odds ratio (OR) 1.66, 95% CI 1.23 to 2.23, p = 0.001) or ziprasidone (OR 1.66, 95% CI 1.06 to 2.62, p = 0.028) had a higher likelihood of MRI/CT.</p> <p>Conclusion</p> <p>Risperidone-treated patients are more likely to undergo prolactin assessment regardless of prior PPAEs, and more likely to undergo MRI/CT in association with hyperprolactinemia or PPAEs. Thus, a predisposition for more evaluations in risperidone-treated patients may contribute to disproportionate identification and reporting of prevalent pituitary adenoma.</p>http://www.annals-general-psychiatry.com/content/8/1/5 |
| spellingShingle | Wu Jasmanda Mahmoud Ramy Pandina Gahan Gianfrancesco Frank D Wang Ruey H Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study Annals of General Psychiatry |
| title | Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study |
| title_full | Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study |
| title_fullStr | Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study |
| title_full_unstemmed | Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study |
| title_short | Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study |
| title_sort | potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone treated patients a claims based study |
| url | http://www.annals-general-psychiatry.com/content/8/1/5 |
| work_keys_str_mv | AT wujasmanda potentialbiasintestingforhyperprolactinemiaandpituitarytumorsinrisperidonetreatedpatientsaclaimsbasedstudy AT mahmoudramy potentialbiasintestingforhyperprolactinemiaandpituitarytumorsinrisperidonetreatedpatientsaclaimsbasedstudy AT pandinagahan potentialbiasintestingforhyperprolactinemiaandpituitarytumorsinrisperidonetreatedpatientsaclaimsbasedstudy AT gianfrancescofrankd potentialbiasintestingforhyperprolactinemiaandpituitarytumorsinrisperidonetreatedpatientsaclaimsbasedstudy AT wangrueyh potentialbiasintestingforhyperprolactinemiaandpituitarytumorsinrisperidonetreatedpatientsaclaimsbasedstudy |